Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Arvanil and anandamide are compounds with potential immunosuppressive properties.
• Understanding their molecular mechanisms is crucial for therapeutic applications.
• Human peripheral blood mononuclear cells (PBMCs) are key immune cells for studying these effects.

Purpose of the Study:

• To analyze the regulation of gene expression by arvanil and anandamide in human PBMCs.
• To clarify the immunosuppressive properties of these compounds.
• To investigate the role of CD36 in their anti-inflammatory pattern.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) were activated and treated with arvanil and anandamide.
• Microarray technology was employed to analyze gene expression patterns.
• Gene and protein expression of CD36 was quantified.

Main Results:

• Arvanil and anandamide normalized CD36 downregulation in activated PBMCs.
• A distinct gene expression pattern related to cell proliferation was identified.
• Transcriptional control of CD36 by these compounds was demonstrated, with increased protein expression.

Conclusions:

• Arvanil and anandamide modulate gene expression in human PBMCs.
• CD36 plays a potential role in the anti-inflammatory effects of arvanil and anandamide.
• These findings provide insights into the immunosuppressive mechanisms of these compounds.